Arcus Biosciences Highlights Casdatifan Momentum in Call

Arcus Biosciences ((RCUS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Arcus Biosciences’ latest earnings call struck an upbeat tone, with management leaning heavily on impressive new clinical data for casdatifan and a strengthened balance sheet. While executives acknowledged competitive and trial‑specific risks, they argued that differentiated efficacy, a large renal‑cell‑carcinoma market, and a long cash runway collectively outweigh the uncertainties.

Casdatifan Monotherapy Delivers Higher Response Rates

Casdatifan’s 100 mg once‑daily cohort showed a confirmed overall response rate of 45% as of the Jan. 30 data cut, up sharply from 35% in August. Pooled monotherapy data also improved, with confirmed response rising from 31% to 35%, reinforcing management’s confidence that the selected dose is clinically meaningful in heavily pretreated patients.

PFS Data Show Clear Efficacy Edge vs. Belzutifan

Progression‑free survival results were another highlight, with the 100 mg cohort posting a median PFS of 15.1 months on 17.8 months’ median follow‑up. That compares favorably to the 5.6 months reported for Merck’s belzutifan in the same late‑line setting, suggesting casdatifan may offer a roughly 2–3× durability advantage.

Low Primary Progression Backs TKI‑Sparing Frontline Strategy

Arcus emphasized casdatifan’s low primary progression rates, a crucial metric for moving into earlier lines of therapy. In the casdatifan plus zimberelimab cohort, only 9% of the first 23 of 30 patients experienced primary progression, versus about 35% for belzutifan monotherapy in a Phase III trial, strengthening the case for a TKI‑sparing frontline approach.

ARC‑20 Platform Speeds Dose Optimization and Expansion

Management credited the ARC‑20 platform with efficiently generating late‑line monotherapy data in 121 patients, supporting 100 mg once daily as the optimal dose. ARC‑20 also enabled the rapid addition of roughly 90 patients across new cohorts and the activation of about 30 sites in four countries, positioning Arcus to accelerate combinations and Phase III launches.

PEAK‑1 Phase III Targets Fast Path to Market

The PEAK‑1 Phase III trial, testing casdatifan plus cabozantinib against cabozantinib alone in IO‑experienced renal cell carcinoma, is now enrolling. With progression‑free survival as the sole primary endpoint and a goal to fully enroll by year‑end, management framed PEAK‑1 as a high‑confidence, fast‑to‑market strategy aimed at roughly 21,000 patients in major markets.

Casdatifan’s Multi‑Billion‑Dollar Sales Potential

Arcus quantified a sizable commercial opportunity, estimating about $2.5 billion in peak sales for casdatifan in the IO‑experienced setting addressed by PEAK‑1. First‑line use could add more than $3 billion, implying a combined peak revenue potential above $5 billion across first‑ and second‑line RCC, with belzutifan’s roughly $1 billion run rate seen as validating class demand.

Cash Runway to 2028 Supports Clinical Ambitions

The company ended Q4 with $1.0 billion of cash, up from $841 million the prior quarter following a $288 million financing. Management said this war chest should fund operations into at least the second half of 2028, giving Arcus room to prosecute multiple late‑stage trials and its emerging immunology pipeline without near‑term capital pressure.

Q4 Results Show Revenue Growth and Lower R&D Spend

Fourth‑quarter GAAP revenue rose to $33 million from $26 million in Q3, driven largely by the Gilead collaboration, while R&D expense fell to $121 million from $141 million. Despite this sequential decline, management acknowledged that overall operating spend remains high, but signaled a meaningful reset in 2026 as major programs mature.

Immunology Programs Near First‑in‑Human Milestones

Arcus highlighted three advanced inflammation and immunology assets, led by an MRGPRX2 antagonist expected to enter the clinic this year in healthy volunteers. The program could deliver proof‑of‑concept data in chronic inducible urticaria within 9–12 months, while a selective TNF receptor‑1 inhibitor is slated for the clinic in late 2026 or early 2027 with a view to differentiating from existing biologics.

STAR‑121 Futility Check Adds Short‑Term Overhang

Investors face a near‑term binary event with an upcoming STAR‑121 futility analysis in the next few months. While the study is largely enrolled and operational disruption would be limited if stopped, the outcome could materially reshape 2026 R&D spend and inject program‑level uncertainty into the broader casdatifan development story.

Volru Combo Pause Highlights Immune‑Toxicity Challenges

The collaboration with AstraZeneca around volrustomig, an anti‑PD‑1/CTLA‑4 bispecific, hit a speed bump after immune‑related adverse events prompted a study pause and subsequent dose reduction. Management said no new immune events and no primary progressions have emerged at the lower dose, but admitted that future plans and timing for the combo remain under active review.

Facing a Strong Rival in Merck’s Belzutifan

Merck remains slightly ahead in the HIF‑2 inhibitor race and is set to present LITESPARK‑011 data for belzutifan plus lenvatinib at ASCO‑GU. Arcus maintains that casdatifan’s response and PFS profile are differentiating, yet management acknowledged that robust Merck data could raise the competitive bar and affect enrollment dynamics in what is likely to be a two‑player class.

High R&D Burden and Concentrated Revenue Base

Even after the Q4 pullback, R&D expense of $121 million underscores the heavy cost of multiple Phase III programs and expansion cohorts. With most revenue still tied to the Gilead collaboration and 2026 GAAP revenue guided to just $45–55 million, Arcus remains dependent on successful clinical execution and future commercialization to justify its current spending levels.

Execution Risk Around Enrollment and Key Readouts

The medium‑term outlook hinges on timely enrollment and positive readouts for PEAK‑1 and planned frontline Phase III trials. Management stressed that rapid site activation, supportive combo data, and external benchmarks like upcoming LITESPARK results must align, as delays or adverse competitive shifts could materially alter timelines and investor expectations.

Guidance Points to Leaner 2026 and Busy Clinical Year

For 2026, Arcus guided GAAP revenue to $45–55 million and reiterated that its $1.0 billion cash pile should fund operations into at least the second half of 2028. Executives expect operating expenses to decrease meaningfully in 2026, with the scale partly contingent on STAR‑121’s futility outcome, while aiming to complete PEAK‑1 enrollment, start a frontline Phase III, advance two immunology assets into the clinic, and deliver new casdatifan combo data through 2026.

Arcus’ call painted a picture of a company in transition from proof‑of‑concept to late‑stage, commercially minded execution, anchored by standout casdatifan data and a fortified balance sheet. Investors must still weigh sizable R&D spend, competitive pressure from Merck, and trial‑specific risks, but management’s confidence in a multibillion‑dollar RCC opportunity and long cash runway underpinned a distinctly optimistic narrative.